Register Login

ASCENDIS PHARMA A/S (ASND)

SymbolASND
NameASCENDIS PHARMA A/S
SectorHEALTH CARE
RegionEurope
IndustryBiotechnology: Pharmaceutical Preparations
AddressTUBORG BOULEVARD 12, HELLERUP, DK-2900, Denmark
Telephone+45 70222244
Fax—
Email—
Websitehttps://www.ascendispharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001612042
Description

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firms product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Additional info from NASDAQ:
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firms product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

2026-06-30 12:30

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Read more
2026-06-26 20:01

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Read more
2026-06-25 20:01

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

Read more
2026-06-13 20:00

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Read more
2026-06-11 20:01

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Read more
2026-06-08 20:59

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Read more
2026-06-02 20:25

SMITH SCOTT THOMAS 🟢 acquired 100 shares of Ascendis Pharma A/S (ASND) at $219.00 Transaction Date: Jun 02, 2026 | Filing ID: 000179

Read more
2026-06-01 20:11

BIENAIME JEAN JACQUES 🟢 acquired 500 shares of Ascendis Pharma A/S (ASND) at $223.76 Transaction Date: May 29, 2026 | Filing ID: 000177

Read more
2026-06-01 20:10

SMITH SCOTT THOMAS 🟢 acquired 250 shares of Ascendis Pharma A/S (ASND) at $223.32 Transaction Date: May 29, 2026 | Filing ID: 000176

Read more
2026-06-01 17:10

New Form 3/A - Ascendis Pharma A/S <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001610717-26-000175 <b>Size:</b> 16 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT05654701 Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroid… — Hypoparathyroidism Approved_For_Marketing — — ClinicalTrials.gov
NCT07706764 A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents Wi… Phase3 Hypoparathyroidism Recruiting 2026-04-22 2031-08-01 ClinicalTrials.gov
NCT07081997 A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of P… Phase3 Hypoparathyroidism Recruiting 2026-04-16 2028-06-01 ClinicalTrials.gov
NCT07264634 A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating… — Hypoparathyroidism Recruiting 2026-03-19 2028-01-01 ClinicalTrials.gov
NCT07345494 A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Foll… — Hypoparathyroidism Recruiting 2026-02-18 2036-01-01 ClinicalTrials.gov
NCT07221851 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compare… Phase3 Turner Syndrome Recruiting 2025-12-12 2029-03-01 ClinicalTrials.gov
NCT06732895 A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescent… Phase2 Achondroplasia Recruiting 2024-12-10 2027-09-01 ClinicalTrials.gov
NCT06433557 A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Nave… Phase2 Achondroplasia Active_Not_Recruiting 2024-07-26 2027-11-01 ClinicalTrials.gov
NCT06079398 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With … Phase2 Achondroplasia Recruiting 2024-01-23 2028-12-01 ClinicalTrials.gov
NCT05980598 TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for A… Phase2 Head and Neck Neoplasms Terminated 2023-09-29 2025-03-28 ClinicalTrials.gov
NCT05929807 A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of… Phase2 Achondroplasia Enrolling_By_Invitation 2023-06-21 2039-03-01 ClinicalTrials.gov
NCT05820672 A US Non-interventional, Effectiveness and Safety Study of Patients Treated Wit… — Growth Hormone Deficiency Recruiting 2023-03-20 2033-03-01 ClinicalTrials.gov
NCT05775523 A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatr… — Growth Hormone Deficiency Recruiting 2023-03-20 2033-03-01 ClinicalTrials.gov
NCT05598320 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With … Phase2 Achondroplasia Completed 2023-03-03 2025-08-13 ClinicalTrials.gov
NCT05690386 A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatro… Phase2 Turner Syndrome Active_Not_Recruiting 2023-02-15 2027-12-01 ClinicalTrials.gov
NCT05081609 A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in… Phase1 Advanced Solid Tumor Active_Not_Recruiting 2022-01-11 2029-08-01 ClinicalTrials.gov
NCT05246033 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Mu… Phase2 Achondroplasia Unknown 2022-01-05 2024-03-01 ClinicalTrials.gov
NCT05171855 A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Ad… Phase3 Adult Growth Hormone Deficiency Completed 2021-12-16 2024-12-23 ClinicalTrials.gov
NCT04799054 A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients Wi… Phase1 Advanced Solid Tumor Terminated 2021-03-18 2025-12-02 ClinicalTrials.gov
NCT04701203 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Adm… Phase3 Hypoparathyroidism Completed 2021-02-16 2025-01-21 ClinicalTrials.gov
NCT04615273 A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin Wit… Phase3 Growth Hormone Deficiency Completed 2020-12-03 2023-12-01 ClinicalTrials.gov
NCT04085523 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Tr… Phase2 Achondroplasia Completed 2020-06-24 2024-10-01 ClinicalTrials.gov
NCT04326374 Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Ch… Phase3 Growth Hormone Deficiency Unknown 2019-12-30 2022-04-01 ClinicalTrials.gov
NCT04009291 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in … Phase2 Hypoparathyroidism Completed 2019-08-27 2025-04-17 ClinicalTrials.gov
NCT03875534 A Multi-center, Longitudinal, Observational Study of Children With Achondroplas… — Achondroplasia Completed 2019-06-19 2024-01-12 ClinicalTrials.gov
NCT03344458 A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children… Phase3 Growth Hormone Deficiency, Pediatric Completed 2017-12-19 2023-02-21 ClinicalTrials.gov
NCT03305016 A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Grow… Phase3 Growth Hormone Deficiency, Pediatric Completed 2017-11-13 2019-03-19 ClinicalTrials.gov
NCT02781727 A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly… Phase3 Growth Hormone Deficiency, Pediatric Completed 2016-12-13 2019-01-17 ClinicalTrials.gov
NCT03803163 A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in H… Phase1 Healthy Volunteers Terminated 2015-01-01 2015-06-01 ClinicalTrials.gov
NCT01947907 Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekl… Phase2 Growth Hormone Deficiency (GHD) Completed 2013-07-01 2015-09-01 ClinicalTrials.gov
NCT01247675 A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) i… Phase2 Adult Growth Hormone Deficiency Completed 2010-11-01 2011-05-01 ClinicalTrials.gov
NCT01010425 Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH) Phase1 Healthy Completed 2009-11-01 2010-05-01 ClinicalTrials.gov
Total clinical trials: 32
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Palopegteriparatide Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07706764
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Omnitrope Other Phase PHASE2 Adult Growth Hormone Deficiency COMPLETED NCT01247675
ACP-001 (TransCon hGH) Other Phase PHASE2 Adult Growth Hormone Deficiency COMPLETED NCT01247675
Human Growth Hormone Other Phase PHASE2 Growth Hormone Deficiency (GHD) COMPLETED NCT01947907
ACP-001 Other Phase PHASE2 Growth Hormone Deficiency (GHD) COMPLETED NCT01947907
TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT03344458
TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT03305016
Placebo Other Phase PHASE3 Hypoparathyroidism COMPLETED NCT04701203
TransCon PTH Other Phase PHASE3 Hypoparathyroidism COMPLETED NCT04701203
Lonapegsomatropin Other Phase PHASE3 Adult Growth Hormone Deficiency COMPLETED NCT05171855
Somatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Placebo Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Lonapegsomatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Once daily subcutaneous injection of Genotropin Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once weekly subcutaneous injection of TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Placebo for TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT04085523
TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT04085523
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Placebo for TransCon PTH Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT04009291
TransCon PTH Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT04009291
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Human Growth Hormone Other Phase PHASE1 Healthy COMPLETED NCT01010425
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01010425
ACP-001 (TransCon PEG hGH) Other Phase PHASE1 Healthy COMPLETED NCT01010425
Human Growth Hormone Other Phase PHASE2 Growth Hormone Deficiency (GHD) COMPLETED NCT01947907
ACP-001 Other Phase PHASE2 Growth Hormone Deficiency (GHD) COMPLETED NCT01947907
Omnitrope Other Phase PHASE2 Adult Growth Hormone Deficiency COMPLETED NCT01247675
ACP-001 (TransCon hGH) Other Phase PHASE2 Adult Growth Hormone Deficiency COMPLETED NCT01247675
TransCon Treprostinil Other Phase PHASE1 Healthy Volunteers TERMINATED NCT03803163
daily hGH Other Phase PHASE3 Growth Hormone Deficiency UNKNOWN NCT04326374
TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency UNKNOWN NCT04326374
TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT03305016
TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT03305016
Once daily subcutaneous injection of Genotropin Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once weekly subcutaneous injection of TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once daily subcutaneous injection of Genotropin Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once weekly subcutaneous injection of TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once daily subcutaneous injection of Genotropin Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once weekly subcutaneous injection of TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Placebo for TransCon CNP Other Phase PHASE2 Achondroplasia UNKNOWN NCT05246033
TransCon CNP Other Phase PHASE2 Achondroplasia UNKNOWN NCT05246033
TransCon hGH Other Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT03344458
Somatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Placebo Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Lonapegsomatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Somatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Placebo Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Lonapegsomatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Somatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Placebo Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Lonapegsomatropin Other Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
Placebo for TransCon PTH Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT04009291
TransCon PTH Other Phase PHASE2 Hypoparathyroidism COMPLETED NCT04009291
Placebo for TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT04085523
TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT04085523
Palopegteriparatide (TransCon PTH) Other Preclinical Hypoparathyroidism APPROVED_FOR_MARKETING NCT05654701
Palopegteriparatide (TransCon PTH) Other Preclinical Hypoparathyroidism APPROVED_FOR_MARKETING NCT05654701
TransCon IL-2 β/γ Other Phase PHASE2 Head and Neck Neoplasms TERMINATED NCT05980598
Pembrolizumab Other Phase PHASE2 Head and Neck Neoplasms TERMINATED NCT05980598
TransCon TLR7/8 Agonist Other Phase PHASE2 Head and Neck Neoplasms TERMINATED NCT05980598
TransCon CNP Other Phase PHASE2 Achondroplasia ENROLLING_BY_INVITATION NCT05929807
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Lonapegsomatropin Other Phase PHASE3 Adult Growth Hormone Deficiency COMPLETED NCT05171855
Lonapegsomatropin Other Phase PHASE3 Adult Growth Hormone Deficiency COMPLETED NCT05171855
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Somatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin Other Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Placebo for TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT05598320
TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT05598320
Placebo for TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT05598320
TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT05598320
Placebo for TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT05598320
TransCon CNP Other Phase PHASE2 Achondroplasia COMPLETED NCT05598320
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05775523
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05775523
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05775523
Placebo Other Phase PHASE3 Hypoparathyroidism COMPLETED NCT04701203
TransCon PTH Other Phase PHASE3 Hypoparathyroidism COMPLETED NCT04701203
Placebo Other Phase PHASE3 Hypoparathyroidism COMPLETED NCT04701203
TransCon PTH Other Phase PHASE3 Hypoparathyroidism COMPLETED NCT04701203
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections Other Phase PHASE2 Achondroplasia ACTIVE_NOT_RECRUITING NCT06433557
Trastuzumab emtansine (T-DM1) Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Trastuzumab Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Surgery Procedure Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
TransCon TLR7/8 Agonist Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Chemotherapy drug Drug Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Pembrolizumab Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
TransCon IL-2 β/γ Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Trastuzumab emtansine (T-DM1) Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Trastuzumab Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Surgery Procedure Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
TransCon TLR7/8 Agonist Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Chemotherapy drug Drug Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Pembrolizumab Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
TransCon IL-2 β/γ Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Palopegteriparatide Other Preclinical Hypoparathyroidism RECRUITING NCT07345494
Placebo for Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06079398
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06079398
Pembrolizumab Other Phase PHASE1 Advanced Solid Tumor TERMINATED NCT04799054
TransCon TLR7/8 Agonist Other Phase PHASE1 Advanced Solid Tumor TERMINATED NCT04799054
Palopegteriparatide Other Preclinical Hypoparathyroidism RECRUITING NCT07264634
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Palopegteriparatide Control Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Palopegteriparatide Experimental Arm Other Phase PHASE3 Hypoparathyroidism RECRUITING NCT07081997
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
No intervention Other Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Somatropin Pen Injector Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Lonapegsomatropin [SKYTROFA®] Other Phase PHASE3 Turner Syndrome RECRUITING NCT07221851
Placebo for navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Navepegritide Other Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Palopegteriparatide Other Preclinical Hypoparathyroidism RECRUITING NCT07264634
Palopegteriparatide DRUG Preclinical Hypoparathyroidism RECRUITING NCT07345494
Placebo for navepegritide DRUG Phase PHASE2 Achondroplasia RECRUITING NCT06732895
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections DRUG Phase PHASE2 Achondroplasia ACTIVE_NOT_RECRUITING NCT06433557
Placebo for Navepegritide DRUG Phase PHASE2 Achondroplasia RECRUITING NCT06079398
Navepegritide DRUG Phase PHASE2 Achondroplasia RECRUITING NCT06079398
No intervention OTHER Preclinical Growth Hormone Deficiency RECRUITING NCT05820672
Palopegteriparatide (TransCon PTH) DRUG Preclinical Hypoparathyroidism APPROVED_FOR_MARKETING NCT05654701
Trastuzumab emtansine (T-DM1) DRUG Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Trastuzumab DRUG Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Surgery PROCEDURE Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
Chemotherapy drug DRUG Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT05081609
TransCon IL-2 β/γ DRUG Phase PHASE2 Head and Neck Neoplasms TERMINATED NCT05980598
Pembrolizumab DRUG Phase PHASE2 Head and Neck Neoplasms TERMINATED NCT05980598
TransCon TLR7/8 Agonist DRUG Phase PHASE2 Head and Neck Neoplasms TERMINATED NCT05980598
Somatropin DRUG Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
Lonapegsomatropin BIOLOGICAL Phase PHASE2 Turner Syndrome ACTIVE_NOT_RECRUITING NCT05690386
daily hGH DRUG Phase PHASE3 Growth Hormone Deficiency UNKNOWN NCT04326374
Placebo for TransCon CNP DRUG Phase PHASE2 Achondroplasia COMPLETED NCT05598320
TransCon CNP DRUG Phase PHASE2 Achondroplasia ENROLLING_BY_INVITATION NCT05929807
TransCon Treprostinil DRUG Phase PHASE1 Healthy Volunteers TERMINATED NCT03803163
TransCon hGH DRUG Phase PHASE3 Growth Hormone Deficiency UNKNOWN NCT04326374
Once daily subcutaneous injection of Genotropin DRUG Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
Once weekly subcutaneous injection of TransCon hGH DRUG Phase PHASE3 Growth Hormone Deficiency, Pediatric COMPLETED NCT02781727
ACP-001 DRUG Phase PHASE2 Growth Hormone Deficiency (GHD) COMPLETED NCT01947907
Omnitrope DRUG Phase PHASE2 Adult Growth Hormone Deficiency COMPLETED NCT01247675
ACP-001 (TransCon hGH) DRUG Phase PHASE2 Adult Growth Hormone Deficiency COMPLETED NCT01247675
Human Growth Hormone DRUG Phase PHASE2 Growth Hormone Deficiency (GHD) COMPLETED NCT01947907
Placebo OTHER Phase PHASE3 Growth Hormone Deficiency COMPLETED NCT04615273
ACP-001 (TransCon PEG hGH) DRUG Phase PHASE1 Healthy COMPLETED NCT01010425
Total products: 295